onr:"swepub:oai:DiVA.org:uu-62918"
Search: onr:"swepub:oai:DiVA.org:uu-62918" > 5alfa-reductase 2 p...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Söderström, TorbjörnUppsala universitet,Institutionen för medicinska vetenskaper (author)
5alfa-reductase 2 polymorphisms as risk factors in prostate cancer
- Article/chapterEnglish2002
Publisher, publication year, extent ...
- Ovid Technologies (Wolters Kluwer Health),2002
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:uu-62918
- https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-62918URI
- http://kipublications.ki.se/Default.aspx?queryparsed=id:1941300URI
- https://doi.org/10.1097/00008571-200206000-00006DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Prostate cancer is a significant cause of death in Western countries and is under the strong influence of androgens. The steroid 5alpha-reductase 2 catalyzes the metabolism of testosterone into the more potent androgen dihydrotestosterone in the prostate gland. The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride. Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems. The L allelic variant has a lower Vmax/Km ratio than the V variant. In the A49T polymorphism, the T variant has an increased Vmax/Km ratio. We performed a population-based case-control study of the impact of the SRD5A2 V89L and A49T polymorphisms on the risk of prostate cancer. We also studied the relation between the genotypes and age at diagnosis, tumor, node, metastasis stage, differentiation grade, prostate specific antigen and heredity. The study included 175 prostate cancer patients and 159 healthy controls that were matched for age. There was an association with SRD5A2 V89L LL genotype and metastases at the time of diagnosis, OR 5.67 (95% CI 1.44-22.30) when adjusted for age, differentiation grade, T-stage and prostate specific antigen. Heterozygous prostate cancer cases that carried the SRD5A2 A49T AT genotype were significantly younger than cases that carried the AA genotype, (mean age 66 years vs 71, P = 0.038). The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk. Further studies of the V89L polymorphism may lead to better understanding of the etiology of prostate cancer metastases.
Subject headings and genre
- prostate cancer
- 5-[alpha] reductase 2
- polymorphism
- metastasis
- MEDICINE
- MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
- Wadelius, MiaUppsala universitet,Klinisk farmakogenomik och osteoporos(Swepub:uu)miawadel (author)
- Andersson, Swen-Olov (author)
- Johansson, Jan-Erik (author)
- Johansson, Sara (author)
- Granath, FredrikKarolinska Institutet (author)
- Rane, AndersKarolinska Institutet (author)
- Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)
Related titles
- In:Pharmacogenetics: Ovid Technologies (Wolters Kluwer Health)12:4, s. 307-120960-314X1473-561X
Internet link
Find in a library
- Pharmacogenetics (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Söderström, Torb ...
- Wadelius, Mia
- Andersson, Swen- ...
- Johansson, Jan-E ...
- Johansson, Sara
- Granath, Fredrik
- show more...
- Rane, Anders
- show less...
- Articles in the publication
- Pharmacogenetics
- By the university
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
